Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

BUY
$0.74 - $7.44 $7,937 - $79,801
10,726 New
10,726 $8,000
Q4 2020

Feb 16, 2021

SELL
$11.65 - $22.07 $3,495 - $6,621
-300 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$8.96 - $14.12 $1,792 - $2,824
200 Added 200.0%
300 $3,000
Q2 2020

Aug 14, 2020

SELL
$7.27 - $14.18 $4,362 - $8,508
-600 Reduced 85.71%
100 $1,000
Q1 2020

May 15, 2020

SELL
$5.27 - $10.41 $1,054 - $2,082
-200 Reduced 22.22%
700 $6,000
Q4 2019

Feb 14, 2020

BUY
$9.46 - $12.16 $1,892 - $2,432
200 Added 28.57%
900 $9,000
Q3 2019

Nov 14, 2019

BUY
$9.01 - $12.55 $1,802 - $2,510
200 Added 40.0%
700 $7,000
Q2 2019

Aug 14, 2019

BUY
$10.25 - $14.36 $5,125 - $7,180
500 New
500 $6,000

Others Institutions Holding SPRO

About Spero Therapeutics, Inc.


  • Ticker SPRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,067,500
  • Market Cap $27.7M
  • Description
  • Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to ...
More about SPRO
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.